Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
| Autor: | Earl, H.M. *, Hiller, L., Dunn, J.A., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Gounaris, I., Abraham, J.E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Rea, D., Caldas, C., Bartlett, J.M.S., Cameron, D.A., Provenzano, E., Thomas, J., Hayward, R.L. |
|---|---|
| Zdroj: | In Annals of Oncology August 2017 28(8):1817-1824 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|